JP Morgan Chase’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$28.2M Sell
207,100
-68,900
-25% -$9.65M ﹤0.01% 1793
2025
Q4
$33.9M Buy
276,000
+31,500
+13% +$3.83M ﹤0.01% 1631
2025
Q3
$27.1M Sell
244,500
-42,000
-15% -$4.77M ﹤0.01% 1847
2025
Q2
$31.8M Buy
286,500
+247,500
+635% +$26.3M ﹤0.01% 1621
2025
Q1
$4.37M Sell
39,000
-34,600
-47% -$3.57M ﹤0.01% 3271
2024
Q4
$6.8M Sell
73,600
-800
-1% -$72K ﹤0.01% 3065
2024
Q3
$6.24M Buy
74,400
+2,700
+4% +$206K ﹤0.01% 3052
2024
Q2
$4.92M Sell
71,700
-23,100
-24% -$1.54M ﹤0.01% 3050
2024
Q1
$6.94M Sell
94,800
-39,400
-29% -$3.03M ﹤0.01% 2803
2023
Q4
$10.9M Sell
134,200
-50,200
-27% -$3.91M ﹤0.01% 2389
2023
Q3
$13.8M Buy
184,400
+115,900
+169% +$8.91M ﹤0.01% 1978
2023
Q2
$5.28M Sell
68,500
-56,200
-45% -$4.48M ﹤0.01% 2814
2023
Q1
$10.3M Sell
124,700
-29,300
-19% -$2.43M ﹤0.01% 2254
2022
Q4
$13.2M Buy
154,000
+42,900
+39% +$3.4M ﹤0.01% 2017
2022
Q3
$6.85M Hold
111,100
﹤0.01% 2460
2022
Q2
$6.87M Sell
111,100
-151,100
-58% -$9.36M ﹤0.01% 2487
2022
Q1
$15.6M Sell
262,200
-293,600
-53% -$18.8M ﹤0.01% 1971
2021
Q4
$40.4M Buy
555,800
+399,900
+257% +$27.5M ﹤0.01% 1327
2021
Q3
$10.9M Sell
155,900
-224,100
-59% -$15.7M ﹤0.01% 2311
2021
Q2
$26.2M Buy
380,000
+329,400
+651% +$22M ﹤0.01% 1608
2021
Q1
$3.27M Sell
50,600
-348,500
-87% -$22.5M ﹤0.01% 3324
2020
Q4
$23.3M Sell
399,100
-207,700
-34% -$12.5M ﹤0.01% 1514
2020
Q3
$37.7M Buy
606,800
+431,800
+247% +$29.9M 0.01% 1121
2020
Q2
$13.5M Sell
175,000
-201,700
-54% -$15.5M ﹤0.01% 1677
2020
Q1
$28.2M Buy
376,700
+29,300
+8% +$2.02M 0.01% 1061
2019
Q4
$22.6M Buy
347,400
+259,400
+295% +$16.9M ﹤0.01% 1495
2019
Q3
$5.58M Sell
88,000
-100,000
-53% -$6.54M ﹤0.01% 2614
2019
Q2
$12.6M Sell
188,000
-351,300
-65% -$23.1M ﹤0.01% 1912
2019
Q1
$35.1M Buy
539,300
+321,700
+148% +$21.4M 0.01% 1164
2018
Q4
$13.6M Sell
217,600
-275,100
-56% -$19.2M ﹤0.01% 1775
2018
Q3
$38M Buy
492,700
+180,000
+58% +$13.6M 0.01% 1186
2018
Q2
$22.2M Buy
312,700
+67,000
+27% +$4.73M ﹤0.01% 1507
2018
Q1
$18.5M Sell
245,700
-211,900
-46% -$16.8M ﹤0.01% 1563
2017
Q4
$32.8M Sell
457,600
-980,000
-68% -$74.4M 0.01% 1222
2017
Q3
$116M Buy
1,437,600
+1,192,200
+486% +$91.2M 0.03% 563
2017
Q2
$17.4M Buy
245,400
+5,400
+2% +$359K ﹤0.01% 1555
2017
Q1
$16.3M Buy
240,000
+138,700
+137% +$9.75M ﹤0.01% 1595
2016
Q4
$7.25M Sell
101,300
-63,100
-38% -$4.69M ﹤0.01% 2154
2016
Q3
$13M Buy
164,400
+78,400
+91% +$6.37M ﹤0.01% 1620
2016
Q2
$7.17M Sell
86,000
-259,000
-75% -$23M ﹤0.01% 2057
2016
Q1
$31.7M Buy
345,000
+17,600
+5% +$1.59M 0.01% 1043
2015
Q4
$33.1M Buy
327,400
+221,500
+209% +$23M 0.01% 1020
2015
Q3
$10.4M Sell
105,900
-118,144
-53% -$13.1M ﹤0.01% 1734
2015
Q2
$26.2M Sell
224,044
-347,989
-61% -$38M 0.01% 1238
2015
Q1
$56.1M Buy
572,033
+72,585
+15% +$7.37M 0.01% 839
2014
Q4
$47.1M Buy
499,448
+283,447
+131% +$29.3M 0.01% 957
2014
Q3
$23M Buy
+216,001
New +$21.2M 0.01% 1358
2014
Q1
Sell
-37,100
Closed -$2.79M 3702
2013
Q4
$2.79M Sell
37,100
-33,900
-48% -$2.36M ﹤0.01% 2544
2013
Q3
$4.46M Sell
71,000
-12,100
-15% -$723K ﹤0.01% 2256
2013
Q2
$4.26M Buy
+83,100
New +$4.33M ﹤0.01% 2245

Other funds holding GILD

JP Morgan Chase's GILD Position: Q1 2026 in Review

JP Morgan Chase increased its Gilead Sciences (GILD) stake by 48% in Q1 2026, buying an estimated $1.53B and bringing the position to 33,992,410 shares worth $4.63B. The position accounts for 0.3% of the portfolio, ranked #69.

JP Morgan Chase first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • JP Morgan Chase held 33,992,410 shares of Gilead Sciences worth $4.63B as of Q1 2026.
  • JP Morgan Chase bought 10,956,647 Gilead Sciences shares in Q1 2026, an estimated $1.53B.
  • Gilead Sciences made up 0.3% of JP Morgan Chase's portfolio in Q1 2026, its #69 holding.
  • JP Morgan Chase first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.